Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

Герпесвирусы и воспалительные заболевания кишечника

https://doi.org/10.31146/1682-8658-ecg-183-11-126-139

Полный текст:

Аннотация

Цель. Провести обзор исследований, характеризующих роль герпесвирусных инфекций в патогенезе воспалительных заболеваний кишечника (ВЗК).

Введение. Изучение роли герпесвирусных инфекций в патогенезе ВЗК в настоящее время вызывает значительный интерес исследователей разных стран.

Результат. Приведены результаты исследований о значении вирусов герпеса человека (HHV) при воспалительных заболеваниях кишечника (ВЗК) — язвенном колите (ЯК) и болезни Крона (БК), их влиянии на течение этих заболеваний, рефрактерности к лечению ЯК и БК в присутствии HHV. Показано, что большинство исследователей единодушно приходят к выводу о том, что основное внимание необходимо уделять вирусу Эпштейна-Барр (EBV), цитомегаловирусу (CMV) и вирусу герпеса человека 6 типа (HHV-6), которые обнаруживаются в слизистой оболочке толстой кишки у пациентов с ВЗК и влияют как на течение заболеваний, так и на эффективность лечения. Акцентируется внимание на том, что необходимо дифференцировать колит, обусловленный HHV, и ВЗК, протекающие на фоне реактивации HHV, так как подходы к терапии этих состояний различны.

Заключение. Необходимы целенаправленные исследования на изучение роли герпесвирусов человека в патогенезе ВЗК.

Об авторах

Г. В. Волынец
Российский национальный исследовательский медицинский университет им. Н. И. Пирогова
Россия

Волынец Галина Васильевна, д. м. н., заведующая отделом гастроэнтерологии, главный научный сотрудник ОСП НИКИ педиатрии им. академика Ю. Е. Вельтищева

125412, Москва, Талдомская улица, дом 2



А. И. Хавкин
Российский национальный исследовательский медицинский университет им. Н. И. Пирогова
Россия

Хавкин Анатолий Ильич, д. м. н., профессор, главный научный сотрудник отдела гастроэнтерологии ОСП НИКИ педиатрии им. академика Ю. Е. Вельтищева

125412, Москва, Талдомская улица, дом 2



А. В. Никитин
Российский национальный исследовательский медицинский университет им. Н. И. Пирогова
Россия

Никитин Артём Вячеславович, к. м. н., ведущий научный сотрудник отдела гастроэнтерологии ОСП НИКИ педиатрии им. академика Ю. Е. Вельтищева

125412, Москва, Талдомская улица, дом 2



Список литературы

1. Whitley RJ. Herpesviruses. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 68. PMID: 21413307 http://evolve.elsevier.com/Murray/microbiology/

2. Ljungman P. Herpes virus infections in immunocompromised patients: problems and therapeutic interventions. Ann Med. 1993;25(4):329–33. DOI: 10.3109/07853899309147293

3. Abraham C, Cho JH. Infl ammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. DOI: 10.1056/NEJMra0804647

4. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621. DOI: 10.1146/annurev-immunol-030409–101225

5. Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am. 2015;95(6):1105–22. DOI: 10.1016/j.suc.2015.07.006

6. Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 2010;45(3):266–76. DOI: 10.1007/s00535–009–0191-y

7. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8(6):458–66. DOI: 10.1038/nri2340

8. Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn’s disease: NOD2, autophagy and ER stress converge. Gut. 2011;60(11):1580–8. DOI: 10.1136/gut.2009.206466

9. Shimada T, Nagata N, Okahara K, Joya A, Hayashida T, Oka S, et al. PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection. PLoS One. 2017;12(9): e0184699. DOI: 10.1371/journal.pone.0184699

10. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes. 2003;10:60–65. PMID: 14759337

11. Ioshii SO, Teixeira V, Figueiredo TM. Fatal toxic megacolon due to cytomegalovirosis in a patient with ulcerative colitis: case report and review. Arq Gastroenterol. 2002;39(2):111–3. DOI: 10.1590/s000428032002000200008

12. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96(7):2137–42. DOI: 10.1111/j.15720241.2001.03949.x

13. Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A, et al. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis. 2001;33(7):551–8. DOI: 10.1016/s1590–8658(01)80106–7

14. Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn’s disease using the nested polymerase chain reaction. J Med Virol. 1992;38:183–190. DOI: 10.1002/jmv.1890380306

15. Yanai H, Shimizu N, Nagasaki S, Mitani N, Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol. 1999;94(6):1582–6. DOI: 10.1111/j.1572–0241.1999.01148.x

16. Nahar S, Iraha A, Hokama A, Uehara A, Parrott G, Ohira T, et al. Evaluation of a multiplex PCR assay for detection of cytomegalovirus in stool samples from patients with ulcerative colitis. World J Gastroenterol. 2015;21(44):12667–75. DOI: 10.3748/wjg.v21.i44.12667

17. Hosomi S, Watanabe K, Nishida Y, Yamagami H, Yukawa T, Otani K, et al. Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis. Infl amm Bowel Dis. 2018;24(6):1307–1315. DOI: 10.1093/ibd/izy005

18. Härmä M, Höckerstedt K, Lyytikäinen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol. 2006;78(6):800–5. DOI: 10.1002/jmv.20626

19. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis. 2001;183(2):179–184. DOI: 10.1086/317929

20. Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol. 1998;56(3):186–91. PMID: 9783683

21. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, et al. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol. 2011;50(1):31–6. DOI: 10.1016/j.jcv.2010.09.011.

22. Weinberg I, Neuman T, Margalit M, Ayman F, Wolf DG, Ben-Yehuda A. Epstein-Barr virus-related diarrhea or exacerbation of inflammatory bowel disease: diagnostic dilemma. J Clin Microbiol. 2009;47(5):1588–90. DOI: 10.1128/JCM.02477–08.

23. Waldman WJ, Williams MV Jr, Lemeshow S, Binkley P, Guttridge D, Kiecolt-Glaser JK, et al. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun. 2008;22(2):215–23. DOI: 10.1016/j.bbi.2007.07.007

24. Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol. 2001;96(3):773–5. DOI: 10.1111/j.15720241.2001.03620.x

25. Domènech E, Vega R, Ojanguren I, Hernández A, GarciaPlanella E, Bernal I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14:1373–1379. Inflamm Bowel Dis. 2008 Oct;14(10):1373–9. DOI: 10.1002/ibd.20498

26. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365–373. DOI: 10.1097/00000478–20040300000009

27. Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007;13(12):1516–21. DOI: 10.1002/ibd.20253

28. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol. 2006;41:706–711. DOI: 10.1080/00365520500408584

29. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/ effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest. 1997;99(7):1739–50. DOI: 10.1172/JCI119338

30. Nakase H, Chiba T. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflamm Bowel Dis. 2010;16(4):550–1. DOI: 10.1002/ibd.21047.

31. Nakase H, Yoshino T, Honzawa Y, Chiba T. Low prevalence of CMV infection in patients with Crohn’s disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. Dig Dis Sci. 2010;55(5):1498–9. DOI: 10.1007/s10620–0101162–0.

32. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102:331–337. DOI: 10.1111/j.1572–0241.2006.00989.x

33. Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl): S59–65. DOI: 10.1097/01.DCR.0000087486.21981.C6

34. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J. 1998;17(3):200–6. DOI: 10.1097/00006454–199803000–00006

35. Forbes BA, Bonville CA, Dock NL. The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system. J Infect Dis. 1990;162(1):39–45. DOI: 10.1093/infdis/162.1.39

36. Widmann T, Sester U, Gärtner BC, Schubert J, Pfreundschuh M, Köhler H, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One. 2008;3(11): e3634. DOI: 10.1371/journal.pone.0003634.

37. Delbridge MS, Karim MS, Shrestha BM, McKane W. Colitis in a renal transplant patient with human herpesvirus-6 infection. Transpl Infect Dis. 2006;8(4):226–8. DOI: 10.1111/j.1399–3062.2006.00143.x

38. Lamoth F, Jayet PY, Aubert JD, Rotman S, Mottet C, Sahli R, et al. Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol. 2008;80(10):1804–7. DOI: 10.1002/jmv.21268

39. Britt WJ, Boppana S. Human cytomegalovirus virion proteins. Hum Immunol. 2004;65:395–402. DOI:10.1016/j.humimm.2004.02.008

40. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16(9):1620–7. DOI: 10.1002/ibd.21275

41. de Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER, et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res. 1998;39:141–162. DOI: 10.1016/s0166–3542(98)00044–8

42. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119:924–935. DOI: 10.7326/00034819–119–9–199311010–00010

43. Korndewal MJ, Mollema L, Tcherniaeva I, van der Klis F, Kroes AC, Oudesluys-Murphy AM, et al. Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. J Clin Virol. 2015;63:53–58. DOI: 10.1016/j.jcv.2014.11.033

44. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–213. DOI: 10.1002/rmv.655

45. Pembrey L, Raynor P, Griffiths P, Chaytor S, Wright J, Hall AJ. Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One. 2013;8: e81881. DOI: 10.1371/journal.pone.0081881

46. Heiden D, Tun N, Maningding E, Heiden M, RoseNussbaumer J, Chan KN, et al. Training clinicians treating HIV to diagnose cytomegalovirus retinitis. Bull World Health Organ. 2014;92(12):903–8. DOI: 10.2471/BLT.14.142372

47. Santos CA, Brennan DC, Fraser VJ, Olsen MA. Incidence, risk factors, and outcomes of delayed-onset cytomegalovirus disease in a large, retrospective cohort of heart transplant recipients. Transplant Proc. 2014;46:35853592. DOI: 10.1016/j.transproceed.2014.08.043

48. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak S, Kos M, Kaic B, Mlinaric-Galinovic G. Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis. Indian J Nephrol. 2015;25:95–98. DOI: 10.4103/0971–4065.139488

49. Weng MT, Tung CC, Lee YS, Leong YL, Shieh MJ, Shun CT, et al. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017;17(1):28. DOI: 10.1186/s12876–017–0586–9

50. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, AllardetServent J, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37(6):1850–7. DOI: 10.1097/CCM.0b013e31819ffea6

51. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13(3): R68. DOI: 10.1186/cc7875

52. Knösel T, Schewe C, Petersen N, Dietel M, Petersen I. Prevalence of infectious pathogens in Crohn’s disease. Pathol Res Pract. 2009;205(4):223–30. DOI: 10.1016/j.prp.2008.04.018

53. Kuwabara A, Okamoto H, Suda T, Ajioka Y, Hatakeyama K. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2007;42:823–829. DOI: 10.1007/s00535–007–2103–3

54. Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis. 2009;3(3):141–8. DOI: 10.1016/j.crohns.2009.03.002

55. Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016;22(3):1321–30. DOI: 10.3748/wjg.v22.i3.1321

56. Takahashi Y, Tange T. Prevalence of cytomegalovirus infection in inflammatory bowel disease patients. Dis Colon Rectum. 2004;47:722–726. DOI: 10.1007/s10350003–0117–3

57. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857–2865. DOI: 10.1111/j.15720241.2006.00869.x

58. Ljungman P, Griffiths P, Paya C. Defi nitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097. DOI: 10.1086/339329

59. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al; European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–68. DOI: 10.1016/j.crohns.2013.12.013

60. Ra EA, Lee TA, Won Kim S, Park A, Choi HJ, Jang I, et al. TRIM31 promotes Atg5/Atg7-independent autophagy in intestinal cells. Nat Commun. 2016;7:11726. DOI: 10.1038/ncomms11726

61. Park SH, Yang SK, Hong SM, Park SK, Kim JW, Lee HJ, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infl iximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58(12):3592–9. DOI: 10.1007/s10620–013–2828–1

62. Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106(11):2001–8. DOI: 10.1038/ajg.2011.202

63. Xue M, Chen SJ, Wang LJ, Du Y, Si JM. Cytomegalovirus: a probable cause of steroid-refractory ulcerative colitis. J Dig Dis. 2013;14:160–165. DOI: 10.1111/1751–2980.12037

64. Nakase H, Matsumura K, Yoshino T, Chiba T. Systematic review: cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2008;43(10):735–40. DOI: 10.1007/s00535–008–2246-x

65. Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(8):725–33. DOI: 10.1111/apt.13124

66. Kim JW, Boo SJ, Ye BD, Kim CL, Yang SK, Kim J, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8(7):693–701. DOI: 10.1016/j.crohns.2013.12.014

67. Abdul-Baki H, Greer JB, Binion DG, Kermanshahi TR, Brand MH, Williams ED, et al. IBD LIVE Case Series-Case 5: The Many Faces of Cytomegalovirus in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(9):2245–54. DOI: 10.1097/MIB.0000000000000843

68. Campos ST, Portela FA, Tomé L. Cytomegalovirus, inflammatory bowel disease, and anti-TNFα. Int J Colorectal Dis. 2017;32(5):645–650. DOI: 10.1007/s00384–017–2752–5

69. Tangye SG, Palendira U, Edwards ES. Human immunity against EBV– lessons from the clinic. J Exp Med. 2017;214(2):269–283. DOI: 10.1084/jem.20161846.

70. Decker LL, Klaman LD, Thorley-Lawson DA. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol. 1996;70(5):3286–9. PMID: 8627812 PMCID: PMC190195

71. Miller G. The switch between latency and replication of Epstein-Barr virus. J Infect Dis. 1990;161(5):833–44. DOI: 10.1093/infdis/161.5.833

72. Young LS, Rickinson AB. Epstein-Barr virus: 40 year son. Nat Rev Cancer. 2004;4(10):757–68. DOI: 10.1038/nrc1452

73. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of EpsteinBarr virus. Nat Med. 2002;8(6):594–9. DOI: 10.1038/nm0602–594

74. Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651–658. DOI: 10.1136/jclinpath-2019–205822

75. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12(2):435–44. DOI: 10.1016/s0889–8588(05)70521–9

76. Straus SE. The chronic mononucleosis syndrome. J Infect Dis. 1988;157(3):405–12. DOI: 10.1093/infdis/157.3.405

77. Kawa K. Epstein-Barr virus – associated diseases in humans. Int J Hematol. 2000;71(2):108–17. PMID: 10745621

78. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673–86. DOI: 10.1182/blood-2011–10–381921.

79. Cohen JI. Epstein–Barr virus infection. N Engl J Med. 2000;343(7):481–92. DOI: 10.1056/NEJM200008173430707

80. Cohen JI, Meyts I. Editorial: EBV Infection and Human Primary Immune Deficiencies. Front Immunol. 2020;11:130. DOI: 10.3389/fimmu.2020.00130

81. Crawford DH. Biology and disease associations of Epstein–Barr virus. Philos Trans R Soc Lond B Biol Sci. 2001;356(1408):461–73. DOI: 10.1098/rstb.2000.0783

82. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34(1):27–53. DOI: 10.1016/s1040–8428(00)00046–9

83. Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. The immunology of Epstein–Barr virus infection. Philos Trans R Soc Lond B Biol Sci. 2001;356(1408):475–88. DOI: 10.1098/rstb.2000.0784

84. Juan A, Lobatón T, Tapia G, Mañosa M, Cabré E, Domènech E. Epstein-Barr virus-positive mucocutaneous ulcer in Crohn’s disease. A condition to consider in immunosuppressed IBD patients. Dig Liver Dis. 2017;49(8):934–937. DOI: 10.1016/j.dld.2017.03.011

85. McGinness JL, Spicknall KE, Mutasim DF. Azathioprineinduced EBV-positive mucocutaneous ulcer. J Cutan Pathol. 2012;39(3):377–81. DOI: 10.1111/j.16000560.2011.01829.x

86. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. DOI: 10.1182/blood-2016–01–643569.

87. Li X, Chen N, You P, Peng T, Chen G, Wang J, et al. The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease. Digestion. 2019;99(2):126–132. DOI: 10.1159/000489996

88. Dimitroulia E, Pitiriga VC, Piperaki ET, Spanakis NE, Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 2013;56(3):322–7. DOI: 10.1097/DCR.0b013e31827cd02c

89. Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, et al. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res. 2016 Feb;64(1):191–203. DOI: 10.1007/s12026–015–8737-y

90. Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus infected cells in inflammatory bowel disease. Am J Pathol. 2000;157(1):51–7. DOI: 10.1016/S0002–9440(10)64516–6

91. Pezhouh MK, Miller JA, Sharma R, Borzik D, Eze O, Waters K, et al. Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in situ hybridization. Hum Pathol. 2018;82:187–192. DOI: 10.1016/j.humpath.2018.08.001

92. Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, et al. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol. 2015;21(6):1915–26. DOI: 10.3748/wjg.v21.i6.1915

93. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267(5):483–501. DOI: 10.1111/j.1365–2796.2010.02220.x

94. Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states. Rev Med Virol. 2014;24(3):142–53. DOI: 10.1002/rmv.1780

95. Vogl BA, Fagin U, Nerbas L, Schlenke P, Lamprecht P, Jabs WJ. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus–specific T lymphocytes and their association with intermittent viral reactivation. J Med Virol. 2012;84(1):119–31. DOI: 10.1002/jmv.22258

96. Lapsia S, Koganti S, Spadaro S, Rajapakse R, Chawla A, Bhaduri-McIntosh S. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation. J Med Virol. 2016;88(2):312–8. DOI: 10.1002/jmv.24331

97. Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122(1):72–7. DOI: 10.1053/gast.2002.30328

98. Lopes S, Andrade P, Conde S, Liberal R, Dias CC, Fernandes S, et al. Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence? Inflamm Bowel Dis. 2017;23(8):1278–1284. DOI: 10.1097/MIB.0000000000001167

99. Moran NR, Webster B, Lee KM, Trotman J, Kwan YL, Napoli J, et al. Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn’s disease. World J Gastroenterol. 2015;21(19):6072–6. DOI: 10.3748/wjg.v21.i19.6072

100. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer – a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405–17. DOI: 10.1097/PAS.0b013e3181cf8622

101. Bunn B, van Heerden W. EBV-positive mucocutaneous ulcer of the oral cavity associated with HIV/AIDS. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(6):725–32. DOI: 10.1016/j.oooo.2015.06.028

102. Roberts T, Chen X, Liao J. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. Exp Hematol Oncol. 2016;5:13. DOI: 10.1186/s40164–016–0042–5

103. Satou A, Kohno A, Fukuyama R, Elsayed AA, Nakamura S. Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis. Hum Pathol. 2017;59:147–151. DOI: 10.1016/j.humpath.2016.08.001

104. Matnani R, Peker D. Azathioprine induced Epstein Barr virus-positive mucocutaneous ulcer arising in perianal fistula and abscess associated with Crohn’s disease. J Crohns Colitis. 2014;8(12):1747–8. DOI: 10.1016/j.crohns.2014.08.010

105. Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant. 2016;51(2):300–2. DOI: 10.1038/bmt.2015.245

106. Magalhaes M, Ghorab Z, Morneault J, Akinfolarin J, Bradley G. Age-related Epstein-Barr virus-positive mucocutaneous ulcer: a case report. Clin Case Rep. 2015;3(7):531–4. DOI: 10.1002/ccr3.287

107. Pantry SN, Medveczky PG. Latency, Integration, and Reactivation of Human Herpesvirus-6. Viruses. 2017;9(7). pii: E194. DOI: 10.3390/v9070194

108. Salahuddin S.Z., Ablashi D. V., Markham P. D., Josephs S. F., Sturzenegger S., Kaplan M., et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986;234(4776):596–601. DOI: 10.1126/science.2876520

109. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005;18(1):217–45. DOI: 10.1128/CMR.18.1.217–245.2005

110. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1(8594):1065–7. DOI: 10.1016/s01406736(88)91893–4

111. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432–8. DOI: 10.1056/NEJM199408183310703

112. Fida M, Hamdi AM, Bryson A, Razonable RR, Abu Saleh O. Long-term Outcomes of Patients With Human Herpesvirus 6 Encephalitis. Open Forum Infect Dis. 2019;6(7): ofz269. DOI: 10.1093/ofid/ofz269

113. Agut H. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J Clin Virol. 2011;52(3):164–71. DOI: 10.1016/j.jcv.2011.06.008

114. Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33(6):829–33. DOI: 10.1086/322691

115. Bates M, Monze M, Bima H, Kapambwe M, Clark D, Kasolo FC, et al. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. J Med Virol. 2009;81(5):779–89. DOI: 10.1002/jmv.21455

116. King A.M.Q., Adams M. J., Carstens E. B., Lefkowitz E. J. Virus Taxonomy. Classification and Nomenclature of Viruses. Ninth Report of the International Committee on Taxonomy of Viruses. International Union of Microbiological Societies Virology Division.Typeset by MPS Limited, a Macmillan Company, Chennai, India www.macmillansolutions.com 2012, 210p. ISBN: 978–0–12–384684–6 http://www.elsevierdirect.com

117. Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant. 2015;50(8):1030–6. DOI: 10.1038/bmt.2015.76

118. Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol. 2012;22(3):144–55. DOI: 10.1002/rmv.715

119. Endo A, Watanabe K, Ohye T, Suzuki K, Matsubara T, Shimizu N, et al. Molecular and virological evidence of viral activation from chromosomally integrated human herpesvirus 6A in a patient with X-linked severe combined immunodeficiency. Clin Infect Dis. 2014;59(4):545–8. DOI: 10.1093/cid/ciu323

120. Ward KN, Leong HN, Nacheva EP, Howard J, Atkinson CE, Davies NW, et al. Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol. 2006;44(4):1571–4. DOI: 10.1128/JCM.44.4.1571–1574.2006

121. Deng Z, Wang Z, Lieberman PM. Telomeres and viruses: common themes of genome maintenance. Front Oncol. 2012;2:201. DOI: 10.3389/fonc.2012.00201

122. Arbuckle J.H., Medveczky P. G. The molecular biology of human herpesvirus-6 latency and telomere integration. Microbes Infect. 2011;13(8–9):731–41. DOI: 10.1016/j.micinf.2011.03.006

123. Godet A.N., Soignon G., Koubi H., Bonnafous P., Agut H., Poirot C., et al. Presence of HHV-6 genome in spermatozoa in a context of couples with low fertility: what type of infection? Andrologia. 2015;47(5):531–5. DOI: 10.1111/and.12299

124. Morissette G., Flamand L. Herpesviruses and chromosomal integration. J Virol. 2010;84(23):12100–9. DOI: 10.1128/JVI.01169–10

125. Ciccocioppo R, Baldanti F, Russo M, Chezzi L, Viola F, Aloi M, et al. Human herpes virus-6 chromosomal integration misled the management of Crohn’s disease. Inflamm Bowel Dis. 2011;17(8): E113–5. DOI: 10.1002/ibd.21790

126. Sura R, Gavrilov B, Flamand L, Ablashi D, Cartun R, Colombel JF, et al. Human herpesvirus-6 in patients with Crohn’s disease. APMIS. 2010;118(5):394–400. DOI: 10.1111/j.1600–0463.2010.02613.x

127. Halme L, Loginov R, Arola J, Turunen U, Lautenschlager I. HHV-6 antigen and HHV-6 DNA expression in sporadic adenomatous polyps of the colon. Scand J Gastroenterol. 2013;48(12):1423–7. DOI: 10.3109/00365521.2013.843200

128. Sipponen T, Turunen U, Lautenschlager I, Nieminen U, Arola J, Halme L. Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2011;46(11):1324–33. DOI: 10.3109/00365521.2011.605466


Для цитирования:


Волынец Г.В., Хавкин А.И., Никитин А.В. Герпесвирусы и воспалительные заболевания кишечника. Экспериментальная и клиническая гастроэнтерология. 2020;183(11):126-139. https://doi.org/10.31146/1682-8658-ecg-183-11-126-139

For citation:


Volynets G.V., Khavkin A.I., Nikitin A.V. Herpesvirus and inflammatory bowel disease. Experimental and Clinical Gastroenterology. 2020;183(11):126-139. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-183-11-126-139

Просмотров: 441


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)